Literature DB >> 19680620

[PSA--Quo vadis?].

C Börgermann1, H Loertzer, H-J Luboldt, P Hammerer, P Fornara, M Graefen, H Rübben.   

Abstract

Prostate cancer is the most frequent cancer in males. Because of the high cure rates, early detection of prostate cancer should identify organ-confined prostate cancers. An early detection examination should be performed annually starting at the age of 50 years and ending when life expectancy is less than 10 years. Digital rectal examination is supplemented by determination of prostate-specific antigen (PSA). Before the first PSA test, the patient must be informed of possible consequences such as biopsy recommendation and treatment options. A threshold of 4 ng/ml is defined as the indication for prostate biopsy. Imaging methods do not play a major role in early detection of prostate cancer today. Early detection identifies many latent prostate cancers, and patients may receive overtreatment. A possible solution is to change the early detection paradigm from detection of all prostate cancers to identification of aggressive ones. In this article, early detection is discussed based on the recent literature.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19680620     DOI: 10.1007/s00120-009-2076-3

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  56 in total

1.  Mean time to cancer-specific death of apparently clinically localized prostate cancer: policy implications for threshold ages in prostate-specific antigen screening and ablative therapy.

Authors:  A H Horan; M McGehee
Journal:  BJU Int       Date:  2000-06       Impact factor: 5.588

2.  Prostate cancer in men age 50 years or younger: a review of the Department of Defense Center for Prostate Disease Research multicenter prostate cancer database.

Authors:  C V Smith; J J Bauer; R R Connelly; T Seay; C Kane; J Foley; J B Thrasher; L Kusuda; J W Moul
Journal:  J Urol       Date:  2000-12       Impact factor: 7.450

3.  Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era.

Authors:  Anthony V D'Amico; Richard Whittington; S Bruce Malkowicz; Kerri Cote; Marian Loffredo; Delray Schultz; Ming-Hui Chen; John E Tomaszewski; Andrew A Renshaw; Alan Wein; Jerome P Richie
Journal:  Cancer       Date:  2002-07-15       Impact factor: 6.860

Review 4.  Long-term survival and mortality in prostate cancer treated with noncurative intent.

Authors:  G Aus; J Hugosson; L Norlén
Journal:  J Urol       Date:  1995-08       Impact factor: 7.450

5.  Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial.

Authors:  Anna Bill-Axelson; Lars Holmberg; Frej Filén; Mirja Ruutu; Hans Garmo; Christer Busch; Stig Nordling; Michael Häggman; Swen-Olof Andersson; Stefan Bratell; Anders Spångberg; Juni Palmgren; Hans-Olov Adami; Jan-Erik Johansson
Journal:  J Natl Cancer Inst       Date:  2008-08-11       Impact factor: 13.506

6.  Influence of age and prostate-specific antigen on the chance of curable prostate cancer among men with nonpalpable disease.

Authors:  H B Carter; J I Epstein; A W Partin
Journal:  Urology       Date:  1999-01       Impact factor: 2.649

7.  Natural history of early, localized prostate cancer.

Authors:  Jan-Erik Johansson; Ove Andrén; Swen-Olof Andersson; Paul W Dickman; Lars Holmberg; Anders Magnuson; Hans-Olov Adami
Journal:  JAMA       Date:  2004-06-09       Impact factor: 56.272

8.  Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men.

Authors:  William J Catalona; Jerome P Richie; Frederick R Ahmann; M'Liss A Hudson; Peter T Scardino; Robert C Flanigan; Jean B DeKernion; Timothy L Ratliff; Louis R Kavoussi; Bruce L Dalkin; W Bedford Waters; Michael T MacFarlane; Paula C Southwick
Journal:  J Urol       Date:  1994-05       Impact factor: 7.450

9.  Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.

Authors:  Ian M Thompson; Donna K Pauler; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Howard L Parnes; Lori M Minasian; Leslie G Ford; Scott M Lippman; E David Crawford; John J Crowley; Charles A Coltman
Journal:  N Engl J Med       Date:  2004-05-27       Impact factor: 91.245

Review 10.  Overdiagnosis and overtreatment of early detected prostate cancer.

Authors:  C H Bangma; S Roemeling; F H Schröder
Journal:  World J Urol       Date:  2007-02-14       Impact factor: 4.226

View more
  3 in total

1.  [Antiandrogen strategies in prostate cancer: reconstitution of oestrogen receptor beta].

Authors:  P Thelen; A Strauss; M Stettner; S Kaulfuss; R-H Ringert; H Loertzer
Journal:  Urologe A       Date:  2010-09       Impact factor: 0.639

2.  [Criteria for errors in prostate-specific antigen diagnostics].

Authors:  V Lent; F Baumbusch; B Weber
Journal:  Urologe A       Date:  2012-11       Impact factor: 0.639

Review 3.  [How to use PSA in 2009].

Authors:  Anton Ponholzer; Franz Stoiber; Wolfgang Loidl; Michael Rauchenwald; Paul Schramek; Stephan Madersbacher
Journal:  Wien Med Wochenschr       Date:  2009
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.